591 related articles for article (PubMed ID: 31595147)
1. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
[TBL] [Abstract][Full Text] [Related]
2. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction.
Tan Z; Lei Y; Xu J; Shi S; Hua J; Zhang B; Meng Q; Liu J; Zhang Y; Wei M; Yu X; Liang C
Aging (Albany NY); 2020 Nov; 12(23):24228-24241. PubMed ID: 33226369
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer survival analysis defines a signature that predicts outcome.
Raman P; Maddipati R; Lim KH; Tozeren A
PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
[TBL] [Abstract][Full Text] [Related]
4. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
Hu Y; Chen Y
Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
[TBL] [Abstract][Full Text] [Related]
5. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
6. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.
Chen D; Huang H; Zang L; Gao W; Zhu H; Yu X
Front Immunol; 2021; 12():728062. PubMed ID: 34691034
[TBL] [Abstract][Full Text] [Related]
7. Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma.
Peng T; Sun F; Yang JC; Cai MH; Huai MX; Pan JX; Zhang FY; Xu LM
World J Gastroenterol; 2024 May; 30(19):2575-2602. PubMed ID: 38817665
[TBL] [Abstract][Full Text] [Related]
8. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
Han Y; Drobisch P; Krüger A; William D; Grützmann K; Böthig L; Polster H; Seifert L; Seifert AM; Distler M; Pecqueux M; Riediger C; Plodeck V; Nebelung H; Weber GF; Pilarsky C; Kahlert U; Hinz U; Roth S; Hackert T; Weitz J; Wong FC; Kahlert C
J Hematol Oncol; 2023 Feb; 16(1):7. PubMed ID: 36737824
[TBL] [Abstract][Full Text] [Related]
9. Construction of a prognostic prediction system for pancreatic ductal adenocarcinoma to investigate the key prognostic genes.
Zheng B; Peng J; Mollayup A; Bakri A; Guo L; Zheng J; Xu H
Mol Med Rep; 2018 Jan; 17(1):216-224. PubMed ID: 29115420
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Implications of an Autophagy-related Gene Signature in Pancreatic Ductal Adenocarcinoma.
Liu WS; Feng YX; Li SN; Shao YJ; Wang K
Am J Clin Oncol; 2022 Mar; 45(3):95-104. PubMed ID: 35195559
[TBL] [Abstract][Full Text] [Related]
11. A 15-Inflammation-Related Gene Signature Predicts the Prognosis of Patients With Pancreatic Ductal Adenocarcinoma.
Sun X; Song H; Sun X; Liao C; Wang G; Xu Y; Li L; Han Y; Xu C; Wang W; Cai S; Liang H; Yu H
Cancer Invest; 2024 Mar; 42(3):226-242. PubMed ID: 38616304
[TBL] [Abstract][Full Text] [Related]
12. A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma.
Li A; Ye B; Lin F; Wang Y; Miao X; Jiang Y
Precis Clin Med; 2022 Jun; 5(2):pbac010. PubMed ID: 35694712
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a cancer stem cell-related signature for prognostic prediction in pancreatic ductal adenocarcinoma.
Feng Z; Shi M; Li K; Ma Y; Jiang L; Chen H; Peng C
J Transl Med; 2020 Sep; 18(1):360. PubMed ID: 32958051
[TBL] [Abstract][Full Text] [Related]
14. Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma.
Song J; Xu Q; Zhang H; Yin X; Zhu C; Zhao K; Zhu J
J Cell Biochem; 2018 Jun; 119(6):4559-4569. PubMed ID: 29239017
[TBL] [Abstract][Full Text] [Related]
15. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data.
Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB
DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163
[TBL] [Abstract][Full Text] [Related]
16. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
17. A New Stemness-Related Prognostic Model for Predicting the Prognosis in Pancreatic Ductal Adenocarcinoma.
Huang XY; Qin WT; Su QS; Qiu CC; Liu RC; Xie SS; Hu Y; Zhu SY
Biomed Res Int; 2021; 2021():6669570. PubMed ID: 34671679
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and lncRNA BC008363 an independent prognostic factor in PDAC.
Li J; Liu D; Hua R; Zhang J; Liu W; Huo Y; Cheng Y; Hong J; Sun Y
Pancreatology; 2014; 14(5):385-90. PubMed ID: 25200694
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma.
Wu M; Li X; Liu R; Yuan H; Liu W; Liu Z
J Cancer; 2020; 11(21):6299-6318. PubMed ID: 33033514
[No Abstract] [Full Text] [Related]
20. Construction and validation of a novel immunological model to predict prognosis in pancreatic ductal adenocarcinoma.
Liu J; He M
Int Immunopharmacol; 2024 Jun; 134():112266. PubMed ID: 38761784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
